Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

ASO Author Reflections: Socioeconomic Disparities in Use of Surgery for Gastrointestinal Cancers Are Large and Impactful in Poor-Prognosis Cancers.

Swords DS, Scaife CL.

Ann Surg Oncol. 2020 Feb;27(2):342-343. doi: 10.1245/s10434-019-08063-7. Epub 2019 Nov 4. No abstract available.

PMID:
31686347
2.

Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers.

Swords DS, Mulvihill SJ, Brooke BS, Firpo MA, Scaife CL.

Ann Surg Oncol. 2020 Feb;27(2):333-341. doi: 10.1245/s10434-019-07922-7. Epub 2019 Oct 11.

PMID:
31605347
3.

County-level Variation in Use of Surgery and Cancer-specific Survival for Stage I-II Pancreatic Adenocarcinoma.

Swords DS, Mulvihill SJ, Brooke BS, Stoddard GJ, Firpo MA, Scaife CL.

Ann Surg. 2019 Apr 8. doi: 10.1097/SLA.0000000000003236. [Epub ahead of print]

PMID:
30973391
4.

Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.

Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M.

Nat Med. 2019 May;25(5):861. doi: 10.1038/s41591-019-0433-3.

PMID:
30918364
5.

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.

Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M.

Nat Med. 2019 Apr;25(4):620-627. doi: 10.1038/s41591-019-0367-9. Epub 2019 Mar 4. Erratum in: Nat Med. 2019 Mar 27;:.

6.

Surgeon-Level Variation in Utilization of Local Staging and Neoadjuvant Therapy for Stage II-III Rectal Adenocarcinoma.

Swords DS, Skarda DE, Sause WT, Gawlick U, Cannon GM, Lewis MA, Scaife CL, Gygi JA, Tae Kim H.

J Gastrointest Surg. 2019 Apr;23(4):659-669. doi: 10.1007/s11605-019-04107-1. Epub 2019 Jan 31.

PMID:
30706375
7.

Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity.

Swords DS, Mulvihill SJ, Brooke BS, Skarda DE, Firpo MA, Scaife CL.

Surgery. 2019 Apr;165(4):751-759. doi: 10.1016/j.surg.2018.10.035. Epub 2018 Dec 11.

PMID:
30551868
8.

Facility Variation in Local Staging of Rectal Adenocarcinoma and its Contribution to Underutilization of Neoadjuvant Therapy.

Swords DS, Brooke BS, Skarda DE, Stoddard GJ, Tae Kim H, Sause WT, Scaife CL.

J Gastrointest Surg. 2019 Jun;23(6):1206-1217. doi: 10.1007/s11605-018-4039-8. Epub 2018 Nov 12.

PMID:
30421120
9.

Safety of implementing a sleep protocol in hospitalized patients.

Patterson MM, Scaife CL, Doig AK.

Am J Surg. 2019 Jun;217(6):1112-1115. doi: 10.1016/j.amjsurg.2018.10.017. Epub 2018 Oct 14.

PMID:
30343874
10.

Perioperative antibiotics should be used for placement of implanted central venous ports: A propensity analysis evaluating risk.

Scaife CL, Mone MC, Bowen ME, Swords DS, Zhang C, Presson AP, Nelson EW.

Am J Surg. 2018 Dec;216(6):1135-1143. doi: 10.1016/j.amjsurg.2018.09.022. Epub 2018 Sep 21.

PMID:
30268417
11.

Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.

Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL.

J Gastrointest Surg. 2019 Jul;23(7):1401-1413. doi: 10.1007/s11605-018-3953-0. Epub 2018 Sep 5.

PMID:
30187332
12.

Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making?

Sharib JM, Fonseca AL, Swords DS, Jaradeh K, Bracci PM, Firpo MA, Hatcher S, Scaife CL, Wang H, Kim GE, Mulvihill SJ, Maitra A, Koay EJ, Kirkwood KS.

Surgery. 2018 Dec;164(6):1178-1184. doi: 10.1016/j.surg.2018.07.014. Epub 2018 Aug 28.

PMID:
30170819
13.

Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma.

Swords DS, Mulvihill SJ, Firpo MA, Scaife CL.

JAMA Oncol. 2018 Aug 1;4(8):1129-1130. doi: 10.1001/jamaoncol.2018.2442. No abstract available.

14.

Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins.

Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd S.

ESMO Open. 2018 Jan 27;3(1):e000282. doi: 10.1136/esmoopen-2017-000282. eCollection 2018.

15.

Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery.

Swords DS, Zhang C, Presson AP, Firpo MA, Mulvihill SJ, Scaife CL.

Surgery. 2018 Apr;163(4):753-760. doi: 10.1016/j.surg.2017.10.054. Epub 2017 Dec 13.

PMID:
29248179
16.

Hospital-level Variation in Utilization of Surgery for Clinical Stage I-II Pancreatic Adenocarcinoma.

Swords DS, Mulvihill SJ, Skarda DE, Finlayson SRG, Stoddard GJ, Ott MJ, Firpo MA, Scaife CL.

Ann Surg. 2019 Jan;269(1):133-142. doi: 10.1097/SLA.0000000000002404.

PMID:
28700442
17.

Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma.

Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ.

Surgery. 2017 Jul;162(1):104-111. doi: 10.1016/j.surg.2016.12.029. Epub 2017 Feb 21.

18.

Biomarkers in pancreatic adenocarcinoma: current perspectives.

Swords DS, Firpo MA, Scaife CL, Mulvihill SJ.

Onco Targets Ther. 2016 Dec 9;9:7459-7467. doi: 10.2147/OTT.S100510. eCollection 2016. Review.

19.

Enterovaginal or Vesicovaginal Fistula Control Using a Silicone Cup.

Russell KW, Robinson RE, Mone MC, Scaife CL.

Obstet Gynecol. 2016 Dec;128(6):1365-1368.

PMID:
27824744
20.

Reply: Should we operate for an intra-abdominal emergency in the setting of disseminated cancer?

Scaife CL, Mone MC.

Surgery. 2016 Jun;159(6):1693-1695. doi: 10.1016/j.surg.2016.02.026. Epub 2016 Apr 5. No abstract available.

PMID:
27059637
21.

Reply: Should we operate for an intraabdominal emergency in the setting of disseminated cancer?

Scaife CL, Hewitt K, Sheng X, Russell KW, Mone MC.

Surgery. 2016 Mar;159(3):981-3. doi: 10.1016/j.surg.2015.10.032. Epub 2015 Dec 29. No abstract available.

PMID:
26744244
22.

Routine endoscopic surveillance for local recurrence of rectal cancer is futile.

Martin LA, Gross ME, Mone MC, Whiting CK, Hansen HJ, Mecham EM, Peche W, Scaife CL.

Am J Surg. 2015 Dec;210(6):996-1001; discussion 1001-2. doi: 10.1016/j.amjsurg.2015.06.027. Epub 2015 Sep 11.

PMID:
26453291
23.

The Barcelona Technique for Ileostomy Reversal.

Russell KW, O'Holleran BP, Bowen ME, Mone MC, Scaife CL.

J Gastrointest Surg. 2015 Dec;19(12):2269-72. doi: 10.1007/s11605-015-2929-6. Epub 2015 Sep 4.

PMID:
26341822
24.

Initial Misdiagnosis of Proximal Pancreatic Adenocarcinoma Is Associated with Delay in Diagnosis and Advanced Stage at Presentation.

Swords DS, Mone MC, Zhang C, Presson AP, Mulvihill SJ, Scaife CL.

J Gastrointest Surg. 2015 Oct;19(10):1813-21. doi: 10.1007/s11605-015-2923-z. Epub 2015 Aug 19.

PMID:
26286368
25.

Should we operate for an intra-abdominal emergency in the setting of disseminated cancer?

Scaife CL, Hewitt K, Sheng X, Russell KW, Mone MC.

Surgery. 2015 Sep;158(3):636-45. doi: 10.1016/j.surg.2015.04.024. Epub 2015 Jun 16.

PMID:
26088921
26.

Design, synthesis, and biological evaluation of sulfonyl acrylonitriles as novel inhibitors of cancer metastasis and spread.

Shen Y, Zificsak CA, Shea JE, Lao X, Bollt O, Li X, Lisko JG, Theroff JP, Scaife CL, Ator MA, Ruggeri BA, Dorsey BD, Kuwada SK.

J Med Chem. 2015 Feb 12;58(3):1140-58. doi: 10.1021/jm501437v. Epub 2015 Jan 26.

PMID:
25581261
27.

Wilderness Medical Society practice guidelines for the treatment of acute pain in remote environments: 2014 update.

Russell KW, Scaife CL, Weber DC, Windsor JS, Wheeler AR, Smith WR, Wedmore I, McIntosh SE, Lieberman JR; Wilderness Medical Society.

Wilderness Environ Med. 2014 Dec;25(4 Suppl):S96-104. doi: 10.1016/j.wem.2014.07.016.

PMID:
25498266
28.

Image-guided placement of long-term central venous catheters reduces complications and cost.

Bowen ME, Mone MC, Nelson EW, Scaife CL.

Am J Surg. 2014 Dec;208(6):937-41; discussion 941. doi: 10.1016/j.amjsurg.2014.08.005. Epub 2014 Sep 22.

PMID:
25440481
29.

Tumour eradication using synchronous thermal ablation and Hsp90 chemotherapy with protein engineered triblock biopolymer-geldanamycin conjugates.

Chen Y, Youn P, Pysher TJ, Scaife CL, Furgeson DY.

Int J Hyperthermia. 2014 Dec;30(8):550-64. doi: 10.3109/02656736.2014.974694. Epub 2014 Nov 18.

PMID:
25403416
30.

Wilderness Medical Society practice guidelines for the treatment of acute pain in remote environments.

Russell KW, Scaife CL, Weber DC, Windsor JS, Wheeler AR, Smith W, Wedmore I, McIntosh SE, Lieberman JR; Wilderness Medical Society.

Wilderness Environ Med. 2014 Mar;25(1):41-9. doi: 10.1016/j.wem.2013.10.001. Epub 2014 Jan 21.

PMID:
24462332
31.

Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.

Kendrick ZW, Firpo MA, Repko RC, Scaife CL, Adler DG, Boucher KM, Mulvihill SJ.

HPB (Oxford). 2014 Jul;16(7):670-6. doi: 10.1111/hpb.12199. Epub 2013 Dec 6.

32.

Does travel distance influence length of stay in elective pancreatic surgery?

Jackson KL, Glasgow RE, Mone MC, Sheng X, Mulvihill SJ, Scaife CL.

HPB (Oxford). 2014 Jun;16(6):543-9. doi: 10.1111/hpb.12180. Epub 2013 Nov 7.

33.

A survey of American College of Surgery fellows evaluating their use of antibiotic prophylaxis in the placement of subcutaneously implanted central venous access ports.

Nelson ET, Gross ME, Mone MC, Hansen HJ, Nelson EW, Scaife CL.

Am J Surg. 2013 Dec;206(6):1034-9; discussion 1039-40. doi: 10.1016/j.amjsurg.2013.07.019. Epub 2013 Oct 16.

PMID:
24139669
34.

Umbilical paracentesis for acute hernia reduction in cirrhotic patients.

Russell KW, Mone MC, Scaife CL.

BMJ Case Rep. 2013 Oct 16;2013. pii: bcr2013201304. doi: 10.1136/bcr-2013-201304.

35.

Association between postoperative complications and clinical cancer outcomes.

Scaife CL, Hartz A, Pappas L, Pelletier P, He T, Glasgow RE, Mulvihill SJ.

Ann Surg Oncol. 2013 Dec;20(13):4063-6. doi: 10.1245/s10434-013-3267-0. Epub 2013 Sep 20.

PMID:
24052315
36.

Comparison of intraoperative versus delayed enteral feeding tube placement in patients undergoing a Whipple procedure.

Scaife CL, Hewitt KC, Mone MC, Hansen HJ, Nelson ET, Mulvihill SJ.

HPB (Oxford). 2014 Jan;16(1):62-9. doi: 10.1111/hpb.12072. Epub 2013 Mar 8.

37.

Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.

Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ.

Pancreas. 2013 Mar;42(2):193-7. doi: 10.1097/MPA.0b013e31825e354d.

38.

Does travel distance influence length of stay in elective colorectal surgery?

Jackson KL, Glasgow RE, Hill BR, Mone MC, Sklow B, Scaife CL, Sheng X, Peche WJ.

Dis Colon Rectum. 2013 Mar;56(3):367-73. doi: 10.1097/DCR.0b013e31827e939e.

PMID:
23392153
39.

The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ.

Curr Mol Med. 2013 Mar;13(3):340-51. Review.

40.

Exploiting antitumor immunity to overcome relapse and improve remission duration.

Chen LL, Chen X, Choi H, Sang H, Chen LC, Zhang H, Gouw L, Andtbacka RH, Chan BK, Rodesch CK, Jimenez A, Cano P, Jones KA, Oyedeji CO, Martins T, Hill HR, Schumacher J, Willmore C, Scaife CL, Ward JH, Morton K, Randall RL, Lazar AJ, Patel S, Trent JC, Frazier ML, Lin P, Jensen P, Benjamin RS.

Cancer Immunol Immunother. 2012 Jul;61(7):1113-24. doi: 10.1007/s00262-011-1185-1. Epub 2011 Dec 24.

41.

Roux-en-Y drainage of a pancreatic fistula for disconnected pancreatic duct syndrome after acute necrotizing pancreatitis.

Pearson EG, Scaife CL, Mulvihill SJ, Glasgow RE.

HPB (Oxford). 2012 Jan;14(1):26-31. doi: 10.1111/j.1477-2574.2011.00397.x. Epub 2011 Oct 31.

42.

A comparison of postoperative outcomes utilizing a continuous preperitoneal infusion versus epidural for midline laparotomy.

Gross ME, Nelson ET, Mone MC, Hansen HJ, Sklow B, Glasgow RE, Scaife CL.

Am J Surg. 2011 Dec;202(6):765-9; discussion 770. doi: 10.1016/j.amjsurg.2011.05.016. Epub 2011 Oct 22.

PMID:
22018440
43.

Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma.

Shea JE, Nam KH, Rapoport N, Scaife CL.

HPB (Oxford). 2011 Mar;13(3):153-7. doi: 10.1111/j.1477-2574.2010.00249.x.

44.

Lineage tracing reveals the dynamic contribution of Hes1+ cells to the developing and adult pancreas.

Kopinke D, Brailsford M, Shea JE, Leavitt R, Scaife CL, Murtaugh LC.

Development. 2011 Feb;138(3):431-41. doi: 10.1242/dev.053843.

45.

Antibiotic prophylaxis in the placement of totally implanted central venous access ports.

Scaife CL, Gross ME, Mone MC, Hansen HJ, Litz CL, Nelson ET, Anderson CJ, Wagner G, Gawlick U, Nelson EW.

Am J Surg. 2010 Dec;200(6):719-22; disussion 722-3. doi: 10.1016/j.amjsurg.2010.07.023.

PMID:
21146010
46.

Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.

Poruk KE, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2605-10. doi: 10.1158/1055-9965.EPI-10-0178. Epub 2010 Aug 20.

47.

Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma.

Scaife CL, Shea J, Emerson L, Boucher K, Firpo MA, Beckerle MC, Mulvihill SJ.

HPB (Oxford). 2010 Jun;12(5):352-8. doi: 10.1111/j.1477-2574.2010.00177.x.

48.

Phenotype and genotype of pancreatic cancer cell lines.

Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ.

Pancreas. 2010 May;39(4):425-35. doi: 10.1097/MPA.0b013e3181c15963. Review. Erratum in: Pancreas. 2018 Jul;47(6):e37.

49.

Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging.

Rapoport N, Kennedy AM, Shea JE, Scaife CL, Nam KH.

Mol Pharm. 2010 Feb 1;7(1):22-31. doi: 10.1021/mp900128x.

50.

Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles.

Rapoport NY, Kennedy AM, Shea JE, Scaife CL, Nam KH.

J Control Release. 2009 Sep 15;138(3):268-76. doi: 10.1016/j.jconrel.2009.05.026. Epub 2009 May 25.

Supplemental Content

Loading ...
Support Center